Research programme: CAR T-cell therapies - CancerVax/University of California
Latest Information Update: 15 Jun 2023
At a glance
- Originator University of California at Los Angeles
- Developer CancerVAX Inc; University of California at Los Angeles
- Class Antineoplastics; CAR-T cell therapies; Gene therapies; Immunotherapies
- Mechanism of Action Immunologic cytotoxicity; T lymphocyte replacements
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Research Ewing's sarcoma
Most Recent Events
- 12 Jun 2023 CancerVAX plans a preclinical trial for Ewing's sarcoma in spring of 2024
- 27 May 2021 CancerVax and University of California collaborate to develop immunotherapies for Ewing's Sarcoma
- 27 May 2021 CancerVax and University of California sign a Letter of Intent for a patent application relating to methods of treating Ewing's sarcoma